Dr. Wangjian Zhong
Claim this profileBaptist Health Louisville
Area of expertise
Lung Cancer
Wangjian Zhong has run 5 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Wangjian Zhong has run 3 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Baptist Health Louisville
Baptist Health Paducah
Clinical Trials Wangjian Zhong is currently running
Pirtobrutinib vs Ibrutinib
for Chronic Lymphocytic Leukemia
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib monotherapy in treatment-naïve participants with CLL/SLL with 17p deletions. Participation could last up to six years for Part 1. Participation could last up to 2 years for Part 2.
Recruiting
2 awards
Phase 3
Radiation Therapy + Atezolizumab
for Small Cell Lung Cancer
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy in addition to atezolizumab may extend the time without extensive small cell lung cancer growing or spreading compared to atezolizumab alone.
Recruiting
1 award
Phase 2 & 3
11 criteria
More about Wangjian Zhong
Clinical Trial Related
5 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Wangjian Zhong has experience with
- Carboplatin
- Atezolizumab
- Adjuvant Chemotherapy
- Zimberelimab
- Domvanalimab
- Etrumadenant
Breakdown of trials Wangjian Zhong has run
Lung Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Wangjian Zhong specialize in?
Wangjian Zhong focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage II.
Is Wangjian Zhong currently recruiting for clinical trials?
Yes, Wangjian Zhong is currently recruiting for 2 clinical trials in Louisville Kentucky. If you're interested in participating, you should apply.
Are there any treatments that Wangjian Zhong has studied deeply?
Yes, Wangjian Zhong has studied treatments such as Carboplatin, Atezolizumab, Adjuvant Chemotherapy.
What is the best way to schedule an appointment with Wangjian Zhong?
Apply for one of the trials that Wangjian Zhong is conducting.
What is the office address of Wangjian Zhong?
The office of Wangjian Zhong is located at: Baptist Health Louisville, Louisville, Kentucky 40207 United States. This is the address for their practice at the Baptist Health Louisville.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.